There is an urgent need to develop new drugs to treat human leishmaniasis, a disease that causes debilitating and life-threatening diseases in millions of people worldwide. This project will investigate whether it is possible to develop a new generation of drugs that target a novel metabolic pathway in these parasites that we have shown to be essential for virulence.
One third of the world's population is infected with the protozoan parasite, Toxoplasma gondii, which can cause life-threatening infections. This proposal will utilize new analytical technologies to understand how these parasites are able to survive in a wide variety of different host cells, how they manage to persist within brain and muscle tissue for the life of the patient and how infection may be linked to mental health disorders, such as schizopohrenia.